Canadian clinicians have reported the case of a woman on long-term rosuvastatin treatment who developed rhabdomyolysis within days of starting on canagliflozin.
06-24-2020 | ADA 2020 | Conference coverage | Article
The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes.
A population-based study suggests that treatment with a statin may slow the risk for new and worsening retinopathy in patients with diabetes and dyslipidemia.
Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.